Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy
Authors
Keywords
-
Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 109, Issue -, Pages 108783
Publisher
Elsevier BV
Online
2022-05-10
DOI
10.1016/j.intimp.2022.108783
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
- (2021) Kate J. Dixon et al. Cancers
- Reduced expansion of CD94/NKG2C + NK cells in chronic lymphocytic leukemia and CLL‐like monoclonal B‐cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or NKG2C deletions
- (2021) Anna Puiggros et al. International Journal of Laboratory Hematology
- Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
- (2021) Johannes Duell et al. HAEMATOLOGICA
- The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
- (2021) Patricia Gogesch et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
- (2021) Michelle K. Becker-Hapak et al. Cancer Immunology Research
- Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function
- (2020) Gustavo Rodrigues Rossi et al. Frontiers in Immunology
- How to select IgG subclasses in developing anti-tumor therapeutic antibodies
- (2020) Jifeng Yu et al. Journal of Hematology & Oncology
- Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity
- (2020) Yao Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- NK cells and ILCs in tumor immunotherapy
- (2020) Simona Sivori et al. MOLECULAR ASPECTS OF MEDICINE
- Therapeutic Fc‐fusion proteins: Current analytical strategies
- (2020) Bastiaan L. Duivelshof et al. JOURNAL OF SEPARATION SCIENCE
- Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
- (2019) Karin M. Knudson et al. Journal for ImmunoTherapy of Cancer
- From the “missing self” hypothesis to adaptive NK cells: Insights of NK cell-mediated effector functions in immune surveillance
- (2019) Mario Ernesto Cruz-Muñoz et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy
- (2019) Jianming Wu et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Natural killer cells as a promising therapeutic target for cancer immunotherapy
- (2019) Nayoung Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- The role of cytokines in the regulation of NK cells in the tumor environment
- (2019) Gordana M. Konjević et al. CYTOKINE
- The Natural Cytotoxicity Receptors in Health and Disease
- (2019) Alexander David Barrow et al. Frontiers in Immunology
- Bisecting GlcNAc Is a General Suppressor of Terminal Modification of N-glycan
- (2019) Miyako Nakano et al. MOLECULAR & CELLULAR PROTEOMICS
- Therapeutic peptides: Historical perspectives, current development trends, and future directions
- (2018) Jolene L. Lau et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
- (2018) Frank Vari et al. BLOOD
- The dual effects of a novel peptibody on angiogenesis inhibition and M2 macrophage polarization on sarcoma
- (2018) Xiaoqing Zhu et al. CANCER LETTERS
- Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
- (2018) Mouldy Sioud et al. FASEB JOURNAL
- Computational Design of Antiangiogenic Peptibody by Fusing Human IgG1 Fc Fragment and HRH Peptide: Structural Modeling, Energetic Analysis, and Dynamics Simulation of Its Binding Potency to VEGF Receptor
- (2018) Lin Ning et al. International Journal of Biological Sciences
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics
- (2018) Chunpeng Yang et al. Frontiers in Immunology
- Molecular Design of Peptide-Fc Fusion Drugs
- (2018) Lin Ning et al. CURRENT DRUG METABOLISM
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
- (2017) Laura Chiossone et al. SEMINARS IN IMMUNOLOGY
- Natural killer cell-mediated immunosurveillance of human cancer
- (2017) Karl-Johan Malmberg et al. SEMINARS IN IMMUNOLOGY
- Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
- (2017) Rodrigo Vazquez-Lombardi et al. Nature Communications
- A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries
- (2017) Katja Klausz et al. Oncotarget
- BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands
- (2017) Kimberly Mayes et al. Oncotarget
- Peptide-specific engagement of the activating NK cell receptor KIR2DS1
- (2017) Anaïs Chapel et al. Scientific Reports
- Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
- (2017) Liming Liu Protein & Cell
- Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy
- (2017) Yusuke Mimura et al. Protein & Cell
- Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells
- (2017) Stefanie Maurer et al. OncoImmunology
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Harnessing Fc receptor biology in the design of therapeutic antibodies
- (2016) Peter Sondermann et al. CURRENT OPINION IN IMMUNOLOGY
- IgG Fc Fragment as a Scaffold for Development of Targeted Therapeutics
- (2016) Gordana Knopp et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
- (2016) Bai Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility
- (2016) Kensuke Shiraishi et al. JOURNAL OF GASTROENTEROLOGY
- Targeting natural killer cells in cancer immunotherapy
- (2016) Camille Guillerey et al. NATURE IMMUNOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- PepComposer: computational design of peptides binding to a given protein surface
- (2016) Agnieszka Obarska-Kosinska et al. NUCLEIC ACIDS RESEARCH
- Peptiderive server: derive peptide inhibitors from protein–protein interactions
- (2016) Yuval Sedan et al. NUCLEIC ACIDS RESEARCH
- Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies
- (2016) James Torchia et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
- (2016) Anne Mobergslien et al. Oncotarget
- An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
- (2016) Caroline Jochems et al. Oncotarget
- Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells
- (2016) Maurizio Perdicchio et al. Oncotarget
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
- (2016) Peter S. Kim et al. Oncotarget
- NKp80 Defines a Critical Step during Human Natural Killer Cell Development
- (2016) Aharon G. Freud et al. Cell Reports
- Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering
- (2016) H. Xu et al. Cancer Immunology Research
- Features of Memory-Like and PD-1+ Human NK Cell Subsets
- (2016) Mariella Della Chiesa et al. Frontiers in Immunology
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
- (2015) William R. Strohl BIODRUGS
- The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
- (2015) M. Rosario et al. CLINICAL CANCER RESEARCH
- Newtonian cell interactions shape natural killer cell education
- (2015) Jodie P. Goodridge et al. IMMUNOLOGICAL REVIEWS
- Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model
- (2015) Dimitrios Mathios et al. INTERNATIONAL JOURNAL OF CANCER
- Generation and Preclinical Characterization of an NKp80-Fc Fusion Protein for Redirected Cytolysis of Natural Killer (NK) Cells against Leukemia
- (2015) Gang Deng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- The production of KIR–Fc fusion proteins and their use in a multiplex HLA class I binding assay
- (2015) Hugo G. Hilton et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells
- (2015) Alessandra Zingoni et al. JOURNAL OF IMMUNOLOGY
- In VivoActivation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits AcuteIn VivoHIV-1 Infection in Humanized Mice
- (2015) Kieran Seay et al. JOURNAL OF VIROLOGY
- Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases
- (2015) Marjana Brkic et al. MEDIATORS OF INFLAMMATION
- In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15
- (2015) Ana M. Vuletić et al. MELANOMA RESEARCH
- Fc fusion as a platform technology: potential for modulating immunogenicity
- (2015) Ditza Levin et al. TRENDS IN BIOTECHNOLOGY
- Oncogenic cancer/testis antigens: prime candidates for immunotherapy
- (2015) Morten F. Gjerstorff et al. Oncotarget
- NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
- (2015) Wei Wang Frontiers in Immunology
- Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells
- (2015) Mouldy Sioud et al. Molecular Therapy-Methods & Clinical Development
- Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation
- (2015) Xiaoping Wu et al. Oncotarget
- Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction
- (2014) Yun-Peng Peng et al. BMC CANCER
- A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma
- (2014) Anita Kumar et al. BRITISH JOURNAL OF HAEMATOLOGY
- Natural Killer Cells Eradicate Galectin-1-Deficient Glioma in the Absence of Adaptive Immunity
- (2014) G. J. Baker et al. CANCER RESEARCH
- Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30
- (2014) E. Schlecker et al. CANCER RESEARCH
- Anti-CD37 antibodies for chronic lymphocytic leukemia
- (2014) Tadeusz Robak et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia
- (2014) Julia Steinbacher et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor-released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape from NK Cell Attack
- (2014) Wei Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fc-Optimized NKG2D–Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status
- (2014) Stefanie Raab et al. JOURNAL OF IMMUNOLOGY
- Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
- (2014) S J Busfield et al. LEUKEMIA
- Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
- (2014) N. C. Singha et al. MOLECULAR CANCER THERAPEUTICS
- Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles
- (2014) Ming-Ru Wu et al. NANOTECHNOLOGY
- Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice
- (2014) Hong Qin et al. NATURE MEDICINE
- Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
- (2014) Evan Gomes-Giacoia et al. PLoS One
- The two faces of IL-6 in the tumor microenvironment
- (2014) Daniel T. Fisher et al. SEMINARS IN IMMUNOLOGY
- The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor
- (2013) Laszlo Otvos et al. AMINO ACIDS
- Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
- (2013) Eric O. Long et al. Annual Review of Immunology
- Regulation of Ligands for the NKG2D Activating Receptor
- (2013) David H. Raulet et al. Annual Review of Immunology
- Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
- (2013) W. Xu et al. CANCER RESEARCH
- NK cell-based immunotherapy for malignant diseases
- (2013) Min Cheng et al. Cellular & Molecular Immunology
- Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
- (2013) Timo Rath et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics
- (2013) Mihalis S Kariolis et al. CURRENT OPINION IN BIOTECHNOLOGY
- Association of FcγRIIIa-158V/F with systemic lupus erythematosus in a Chinese population
- (2013) Min Dai et al. International Journal of Rheumatic Diseases
- Membrane-Type 6 Matrix Metalloproteinase Regulates the Activation-Induced Downmodulation of CD16 in Human Primary NK Cells
- (2013) G. Peruzzi et al. JOURNAL OF IMMUNOLOGY
- Pharmacokinetics of Peptide–Fc Fusion Proteins
- (2013) W.U. Benjamin et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131
- (2013) F. Mimoto et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia
- (2012) B. J. Schmiedel et al. CANCER RESEARCH
- The impact of glycosylation on monoclonal antibody conformation and stability
- (2012) Kai Zheng et al. mAbs
- PepSite: prediction of peptide-binding sites from protein surfaces
- (2012) L. G. Trabuco et al. NUCLEIC ACIDS RESEARCH
- Tumor-Targeted Delivery of IL-2 by NKG2D Leads to Accumulation of Antigen-Specific CD8+ T Cells in the Tumor Loci and Enhanced Anti-Tumor Effects
- (2012) Tae Heung Kang et al. PLoS One
- HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy
- (2012) Xinran Xiang et al. Journal of Cancer
- Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy
- (2011) Thanh-Nhan Nguyen-Pham et al. Cellular & Molecular Immunology
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- Introduction to current and future protein therapeutics: A protein engineering perspective
- (2011) Paul J. Carter EXPERIMENTAL CELL RESEARCH
- Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy
- (2011) Andreas Pircher et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
- (2011) Kory L. Alderson et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies
- (2011) Alain Beck et al. mAbs
- Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1
- (2011) Tomasz P. Rygiel et al. MOLECULAR IMMUNOLOGY
- Optimizing Therapeutic Antibody Function
- (2010) Etsuji Kaneko et al. BIODRUGS
- Cytokine regulation of natural killer cell effector functions
- (2010) Norberto W. Zwirner et al. BIOFACTORS
- Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction
- (2010) G. Konjević et al. BIOMEDICINE & PHARMACOTHERAPY
- Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer
- (2010) Zhiwei Hu et al. BMC IMMUNOLOGY
- Delivery of NKG2D Ligand Using an Anti-HER2 Antibody-NKG2D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response
- (2010) H.-M. Cho et al. CANCER RESEARCH
- Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells
- (2010) Y. Kawasaki et al. GLYCOBIOLOGY
- Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
- (2010) Takuo Suzuki et al. JOURNAL OF IMMUNOLOGY
- In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients
- (2010) Gordana Konjević et al. MELANOMA RESEARCH
- pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents
- (2010) Oleg A. Andreev et al. MOLECULAR MEMBRANE BIOLOGY
- IL-15R -IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation
- (2010) Z. Wu et al. Journal of Molecular Cell Biology
- Engineered therapeutic antibodies with improved effector functions
- (2009) Tsuguo Kubota et al. CANCER SCIENCE
- Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
- (2009) Chichi Huang CURRENT OPINION IN BIOTECHNOLOGY
- Immunotherapy of cancer
- (2009) Hossein Borghaei et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
- (2009) Cameron S. Brandt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- NK Cell Responsiveness Is Tuned Commensurate with the Number of Inhibitory Receptors for Self-MHC Class I: The Rheostat Model
- (2009) N. T. Joncker et al. JOURNAL OF IMMUNOLOGY
- Novel Human Interleukin-15 Agonists
- (2009) X. Zhu et al. JOURNAL OF IMMUNOLOGY
- Tumor-Associated MICA Is Shed by ADAM Proteases
- (2008) I. Waldhauer et al. CANCER RESEARCH
- Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery
- (2008) Santiago Vilar et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy
- (2008) Nadia Guerra et al. IMMUNITY
- CNTO 530: Molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice
- (2008) P.J. Bugelski et al. JOURNAL OF BIOTECHNOLOGY
- Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery
- (2008) A. Lo et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies
- (2008) Seung Y. Chu et al. MOLECULAR IMMUNOLOGY
- Up on the tightrope: natural killer cell activation and inhibition
- (2008) Lewis L Lanier NATURE IMMUNOLOGY
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
- NKG2D ligands: key targets of the immune response
- (2008) Segundo González et al. TRENDS IN IMMUNOLOGY
- New aspects of NK cell subset identification and inference of NK cells’ regulatory capacity by assessing functional and genomic profiles
- (2007) Esther Wilk et al. IMMUNOBIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started